There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > B7-H5


Brief Information

Name:V-domain Ig suppressor of T-cell activation
Target Synonym:Dies1,Stress-induced secreted protein-1,PP2135,SISP1,UNQ730/PRO1412,V-type immunoglobulin domain-containing suppressor of T-cell activation,V-Set Immunoregulatory Receptor,V-Domain Ig Suppressor Of T Cell Activation,PDCD1 Homolog,C10orf54,Sisp-1,VISTA,Chr
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Part of Bioactivity data


Human B7-H5, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. B75-H5258) Captured on CM5 chip via anti-mouse antibodies surface can bind Human VSIG3, Fc Tag (Cat. No. VS3-H5258) with an affinity constant of 8.87 μM as determined in a SPR assay (Biacore T200) (Routinely tested).


Human PSGL-1, His Tag (Cat. No. PS1-H52H9) immobilized on CM5 Chip can bind Human B7-H5, Fc Tag (Cat. No. B75-H5259) with an affinity constant of 0.213 μM as determined in a SPR assay (Biacore T200) (Routinely tested).

Synonym Name



Platelet receptor Gi24, also known as B7-H5 and stress-induced secreted protein-1 (Sisp-1), is a protein that in humans is encoded by the C10orf54 gene, which contains 1 Ig-like (immunoglobulin-like) domain. As for C10orf54 gene, C10orf54 appears to positively interact with BMP-4, potentiating BMP signaling and the transition from an undifferentiated to a differentiated state on ESCs. Human C10orf54 undergoes proteolytic cleavage by MT1-MMP, generating a soluble 30 kDa extracellular fragment plus a 25-30 kDa membrane-bound fragment.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Onvatilimab CI-8993; JNJ-61610588 Phase 1 Clinical Janssen Global Services Llc, Immunext Neoplasms Details
CA-170 CA-170; AUPM-170 Phase 2 Clinical Aurigene Solid tumours; Neoplasms Details

This web search service is supported by Google Inc.